The article you requested is
Role of Mirtazapine in the Pharmacotherapy of Depression
J Clin Psychiatry 2000;61(8):609-616
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Academic Highlights: Role of Mirtazapine in the Pharmacotherapy of Depression.
Over more than 30 years, evidence has accumulated confirming the hypothesis that norepinephrine and serotonin play pivotal roles in the mechanism
of action of antidepressant drugs, stated Dr. Alan F. Schatzberg. Many antidepressants from distinct pharmacologic classes are currently available, but all affect one or both of these neurotransmitter systems. The first antidepressants—the tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs)—act mainly on noradrenergic and serotonergic systems, but their affinity for other neuronal systems, such as cholinergic, α1-adrenergic, dopaminergic, and histaminergic, and quinidine-like effects contribute to their poor tolerability profiles. In contrast, the selective serotonin reuptake inhibitors (SSRIs: e.g., fluoxetine, citalopram, paroxetine, sertraline) have no effect on norepinephrine, and affinity for other receptors differs between the